No antimicrobial resistance research agenda without tuberculosis

Knight, Gwenan M.; Raviglione, Mario C.; White, Richard G.

doi:10.1016/s2214-109x(20)30309-0

Cited by 5 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1] In the backdrop of global fight against antimicrobial resistance (AMR), drug resistance TB (DR-TB) poses a serious hurdle, accounting for a quarter of all deaths inflicted by AMR bacteria. [2] Drug susceptible TB (DS-TB) alone requires long courses of multiple antibiotic administration to ensure complete recovery and avert any chances of developing acquired resistance. More complex is the treatment of multidrug-resistant TB (MDR-TB: resistant to 1 st line drugs INH/RIF) that demands a combination of antibiotics over a period of two years with eight months of daily injection and an staggering no.…”

Section: Introductionmentioning

confidence: 99%

Exploration of Isoxazole‐Carboxylic Acid Methyl Ester Based 2‐Substituted Quinoline Derivatives as Promising Antitubercular Agents

Sahoo

Ahmad

Kaul

et al. 2022

Chemistry & Biodiversity

View full text Add to dashboard Cite

In pursuit of potent anti‐TB agents active against drug resistant tuberculosis (DR‐TB), herein we report synthesis and bio‐evaluation of a new series of isoxazole‐carboxylic acid methyl ester based 2‐substituted quinoline derivatives. Preliminary evaluation indicated selectivity towards Mtb H37Rv, with no inhibition of non‐tubercular mycobacterial (NTM) & bacterial pathogen panel. Out of 36 synthesized compounds, majority exhibited substantial inhibition of Mtb H37Rv (MIC 0.5–8 μg/mL). Cell viability test against Vero cells revealed no significant cytotoxicity. Further, screening against drug resistant strains (DR‐Mtb) found hit compound displaying promising potency (MIC 1–4 μg/mL). Structure optimization of the hit led to the identification of lead compound demonstrating potent inhibition of both drug‐susceptible Mtb (MIC 0.12 μg/mL) and drug‐resistant Mtb (MIC 0.25–0.5 μg/mL) along with a high selectivity index (SI) >80. Taken together, with appreciable selectivity and potent activity, these chemotypes show prospect to be turned into a potential anti‐TB candidate.

show abstract

Section: Introductionmentioning

confidence: 99%

Exploration of Isoxazole‐Carboxylic Acid Methyl Ester Based 2‐Substituted Quinoline Derivatives as Promising Antitubercular Agents

Sahoo

Ahmad

Kaul

et al. 2022

Chemistry & Biodiversity

View full text Add to dashboard Cite

show abstract

“…It is also imperative that the Mycobacterium tuberculosis must be included in anti-microbial resistance (AMR) priority list for further research and development. 8 The review will elaborate the summery of diagnosis and constructive research performed in field of Tuberculosis.…”

Section: Introductionmentioning

confidence: 99%

A multidimensional approach to the elimination of tuberculosis

Singh¹,

Bhange²

2022

JBMOA

View full text Add to dashboard Cite

Significant global efforts have been made in recent years to combat tuberculosis (TB) disease. Despite the fact that social and economic causes of TB have been well known for decades, the range of interventions has, until recently, been mostly restricted to the health domain. Mycobacterium tuberculosis that causes tuberculosis, the second-deadliest infectious killer (after COVID-19), which typically damages the lungs. It can spread when TB patients cough or otherwise release bacteria into the air, which can spread the disease. To ensure that significant gaps in outcome-oriented research are recognized and filled, we must promote collaboration among all involved parties in tuberculosis research and control in order to optimise the impact of fundamental research. Consequently, a multisectoral and interdisciplinary strategy is necessary as the global health community works toward the pledges and goals established in two recent high-level political gatherings.

show abstract